{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:26:54Z","timestamp":1793831214881,"version":"4.6.1"},"reference-count":53,"publisher":"BMJ","issue":"14","funder":[{"name":"Prothena Biosciences Inc"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2017,2,4]]},"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>Amyloid light chain (AL) amyloidosis is a systemic disease characterised by the aggregation of misfolded immunoglobulin light chain (LC), predominantly in the heart and kidneys, causing organ failure. If untreated, the median survival of patients with cardiac AL amyloidosis is 6 months from the onset of heart failure. Protracted time to establish a diagnosis, often lasting &gt;1 year, is a frequent factor in poor treatment outcomes. Cardiologists, to whom patients are often referred, frequently miss the opportunity to diagnose cardiac AL amyloidosis. Nearly all typical cardiac support measures, with the exception of diuretics, are ineffective and may even worsen clinical symptoms, emphasising the need for accurate diagnosis. Patients with severe cardiac involvement face poor outcomes; heart transplantation is rarely an option because of multiorgan involvement, rapid clinical decline and challenges in predicting which patients will respond to treatment of the underlying plasma cell disorder. Early diagnosis and prompt treatment with \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153source therapies\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2 that limit the production of amyloidogenic LC are associated with better survival and improvement in organ function after a median of 2.4 months following haematological complete response. However, organ recovery is often incomplete because these source therapies do not directly target deposited amyloid. Emerging amyloid-directed therapies may attenuate, and potentially reverse, organ dysfunction by clearing existing amyloid and inhibiting fibril formation of circulating aggregates. Improved recognition of AL amyloidosis by cardiologists allows for earlier treatment and improved outcomes.<\/jats:p>","DOI":"10.1136\/heartjnl-2016-310704","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T20:10:17Z","timestamp":1493496617000},"page":"1065-1072","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":170,"title":["Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response"],"prefix":"10.1136","volume":"103","clinical-trial-number":[{"clinical-trial-number":"nct01707264","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02632786","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02312206","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01777243","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02245867","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Martha","family":"Grogan","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A","family":"Gertz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,4,29]]},"reference":[{"key":"2025092021572190000_103.14.1065.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-570010"},{"key":"2025092021572190000_103.14.1065.2","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.2015.1093936"},{"key":"2025092021572190000_103.14.1065.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2013.06.051"},{"key":"2025092021572190000_103.14.1065.4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.108.788687"},{"key":"2025092021572190000_103.14.1065.5","doi-asserted-by":"publisher","DOI":"10.1096\/fj.15-272179"},{"key":"2025092021572190000_103.14.1065.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912263107"},{"key":"2025092021572190000_103.14.1065.7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","article-title":"Natural history and therapy of AL cardiac amyloidosis","volume":"20","author":"Grogan","year":"2015","journal-title":"Heart Fail Rev"},{"key":"2025092021572190000_103.14.1065.8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0250-0"},{"key":"2025092021572190000_103.14.1065.9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/asheducation.V2012.1.595.3798563","article-title":"Differential diagnosis of monoclonal gammopathy of undetermined significance","volume":"2012","author":"Merlini","year":"2012","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2025092021572190000_103.14.1065.10","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"2025092021572190000_103.14.1065.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2922"},{"key":"2025092021572190000_103.14.1065.12","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.108"},{"key":"2025092021572190000_103.14.1065.13","doi-asserted-by":"publisher","DOI":"10.1002\/jms.3264"},{"key":"2025092021572190000_103.14.1065.14","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/leu.2016.191","article-title":"Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis","volume":"30","author":"Merlini","year":"2016","journal-title":"Leukemia"},{"key":"2025092021572190000_103.14.1065.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.029"},{"key":"2025092021572190000_103.14.1065.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724"},{"key":"2025092021572190000_103.14.1065.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.843334"},{"key":"2025092021572190000_103.14.1065.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.10.028"},{"key":"2025092021572190000_103.14.1065.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-013-9800-5"},{"key":"2025092021572190000_103.14.1065.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.05.097"},{"key":"2025092021572190000_103.14.1065.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.08.043"},{"key":"2025092021572190000_103.14.1065.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.04.043"},{"key":"2025092021572190000_103.14.1065.23","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jes009"},{"key":"2025092021572190000_103.14.1065.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.785014"},{"key":"2025092021572190000_103.14.1065.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00293-2"},{"key":"2025092021572190000_103.14.1065.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2013.12.010"},{"key":"2025092021572190000_103.14.1065.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2006.06.002"},{"key":"2025092021572190000_103.14.1065.28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.113.001396"},{"key":"2025092021572190000_103.14.1065.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.102053"},{"key":"2025092021572190000_103.14.1065.30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.114.002954"},{"key":"2025092021572190000_103.14.1065.31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.112.000132"},{"key":"2025092021572190000_103.14.1065.32","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2025092021572190000_103.14.1065.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13396-X"},{"key":"2025092021572190000_103.14.1065.34","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24001"},{"key":"2025092021572190000_103.14.1065.35","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood.V124.21.306.306","article-title":"Growth differentiation factor-15 in patients with light chain (AL) amyloidosis has independent prognostic significance and adds prognostic information related to risk of early death and renal outcomes","volume":"124","author":"Kastritis","year":"2014","journal-title":"Blood"},{"key":"2025092021572190000_103.14.1065.36","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2011.627069"},{"key":"2025092021572190000_103.14.1065.37","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1038\/bcj.2015.45","article-title":"Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the mayo staging","volume":"5","author":"Kastritis","year":"2015","journal-title":"Blood Cancer J"},{"key":"2025092021572190000_103.14.1065.38","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21822"},{"key":"2025092021572190000_103.14.1065.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-286567"},{"key":"2025092021572190000_103.14.1065.40","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23141"},{"key":"2025092021572190000_103.14.1065.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.06.009"},{"key":"2025092021572190000_103.14.1065.42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"2025092021572190000_103.14.1065.43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-620302"},{"key":"2025092021572190000_103.14.1065.44","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23898"},{"key":"2025092021572190000_103.14.1065.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2013.01.987"},{"key":"2025092021572190000_103.14.1065.46","doi-asserted-by":"publisher","DOI":"10.1111\/jce.12123"},{"key":"2025092021572190000_103.14.1065.47","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5500\/wjt.v6.i2.380","article-title":"Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience","volume":"6","author":"Grogan","year":"2016","journal-title":"World J Transplant"},{"key":"2025092021572190000_103.14.1065.48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.6530"},{"key":"2025092021572190000_103.14.1065.49","unstructured":"Liedtke M , Comenzo RL , Landau H , et al . NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1\/2 study. Proceedings of the XVth ISA International Symposium of Amyloidosis. Uppsala, Sweden, 2016:3\u20137."},{"key":"2025092021572190000_103.14.1065.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504942"},{"key":"2025092021572190000_103.14.1065.51","unstructured":"Langer A , Gould J , Miao S , et al . Interim analysis of phase 1 study of chimeric fibril-reactive monoclonal antibody 11-1F4V in patients with AL amyloidosis. Proceedings of the XVth ISA International Symposium of Amyloidosis. Uppsala, Sweden, July 2016:3\u20137."},{"key":"2025092021572190000_103.14.1065.52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-351643"},{"key":"2025092021572190000_103.14.1065.53","unstructured":"Wechalekar A , Whelan C , Lachmann H , et al . Oral doxycycline improves outcomes of stage III AL amyloidosis \u2013 a matched case control study. Proceedings of the 57th ASH Annual Meeting and Exposition. Orlando, FL, 2015:5\u20138."}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2016-310704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:57:33Z","timestamp":1758430653000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2016-310704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,29]]},"references-count":53,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2017,6,26]]},"published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1136\/heartjnl-2016-310704"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2016-310704","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,29]]}}}